Celldex Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLDX in the last 7 days.
No SEC Form 4 filings for $CLDX in the last 30 days.
See all $CLDX insider activity →HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics with a $64 price target, implying a 98.9% upside from the Oct 1 close of $32.18. The company's pipeline focuses on severe inflammatory and autoimmune diseases, and surveys indicate positive physician sentiment despite safety concerns.
Celldex's barzolvolimab for chronic urticaria showed low anaphylaxis risk, with no black box expected, but stock reacted negatively. Amgen's dazodalibep for Sjögren's showed positive Phase 3 results, targeting a $25B market. Biotech stocks face sentiment challenges despite positive data.
Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.
Recent CLDX coverage spans technology, financial news and macro economy.
Analyst upgrade and higher price target may lift the stock.
Positive safety data could lift CLDX stock as label risk diminishes.
Positive pivotal data may boost CLDX stock and validate Guggenheim's bullish ranking.
Negative trial outcome adds pressure.
Positive Phase 3 data suggest strong efficacy and may drive near‑term price appreciation.
AlphAI scores every news story that mentions CLDX with an AI model for sentiment and relevance, and aggregates insider trades from Celldex Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained a Buy rating on Celldex Therapeutics with a $64 price target, implying a 98.9% upside from the Oct 1 close of $32.18. The company's pipeline focuses on severe inflammatory and autoimmune diseases, and surveys indicate positive physician sentiment despite safety concerns.
1 min readCelldex's barzolvolimab for chronic urticaria showed low anaphylaxis risk, with no black box expected, but stock reacted negatively. Amgen's dazodalibep for Sjögren's showed positive Phase 3 results, targeting a $25B market. Biotech stocks face sentiment challenges despite positive data.
3 min readGuggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.
2 min readUS PMI data exceeded expectations, with manufacturing and services PMIs at multi-year highs. Wall Street opened lower, with the Dow, S&P 500, and Nasdaq down. IonQ rose 5% after quantum error correction news, while General Mills fell 2% despite earnings beat. Meta's AI agent boosted shares, while biotechs like Viking Therapeutics and Celldex saw mixed movements. FTSE 100 closed flat, with Auto Trader Group leading losses.
3 min readCelldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting all primary and secondary endpoints. The drug showed significant efficacy, with a majority of patients achieving complete symptom relief. However, the company faces high R&D costs and a 2027 expected BLA filing. CLDX has $717.6M in cash and a pipeline of other studies, but a recent Phase 2 failure in prurigo nodularis highlights risks.
3 min readCelldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.
2 min readCelldex (CLDX) reported positive Phase 3 results for Barzolvolimab in chronic hives studies, meeting primary and secondary endpoints. The drug showed rapid and sustained efficacy, with plans to submit a Biologics License Application in 2027. CLDX stock is down 16.57% to $31.67.
2 min readCelldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both studies met primary and secondary endpoints, showing significant symptom improvement. The treatment also showed sustained efficacy and a favorable safety profile. CLDX plans to submit a Biologics License Application to the FDA in 2027. Shares initially rose but later fell 12.51% to $36.65.
2 min readCantor Fitzgerald kept its Overweight rating on Celldex Therapeutics with a $72 price target, implying a 90% upside from the Sep 21 close. The firm cited strong clinical data and substantial market potential for the company's therapies, particularly in treating severe angioedema and chronic spontaneous urticaria.
1 min readCelldex (CLDX) shares fell over 20% premarket Tuesday despite positive late-stage trial results for barzolvolimab, its experimental hives treatment, according to the company.
1 min read
